Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies

HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties...

Descripción completa

Detalles Bibliográficos
Autores principales: Puttemans, Janik, Dekempeneer, Yana, Eersels, Jos L., Hanssens, Heleen, Debie, Pieterjan, Keyaerts, Marleen, Windhorst, Albert D., van der Aa, Frank, Lecocq, Quentin, Breckpot, Karine, Morgenstern, Alfred, Bruchertseifer, Frank, Lahoutte, Tony, Devoogdt, Nick, D’Huyvetter, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226418/
https://www.ncbi.nlm.nih.gov/pubmed/32326199
http://dx.doi.org/10.3390/cancers12041017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226418/
https://www.ncbi.nlm.nih.gov/pubmed/32326199
http://dx.doi.org/10.3390/cancers12041017

Ejemplares similares